LINC01214 Promotes Non-Small Cell Lung Cancer Through the miR-497-3p/HSP90AB1 Axis

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide.
• Identifying novel biomarkers for prognosis and therapy is crucial for improving patient outcomes.
• Long non-coding RNAs (lncRNAs) are increasingly recognized for their roles in cancer development.

Purpose of the Study:

• To investigate the prognostic and therapeutic potential of the lncRNA LINC01214 in non-small cell lung cancer (NSCLC).
• To elucidate the molecular mechanisms underlying LINC01214's role in NSCLC progression.

Main Methods:

• Quantitative real-time PCR (qPCR) and Western blot (WB) were used to quantify molecular levels.
• Kaplan-Meier and Cox regression analyses assessed prognostic effects.
• Cell proliferation, apoptosis, migration, and invasion were evaluated using CCK-8, flow cytometry, and Transwell assays.
• The regulatory axis was verified using dual luciferase reporter and rescue experiments.

Main Results:

• LINC01214 expression was elevated in NSCLC tissues and cell lines, correlating with increased mortality.
• High LINC01214 levels served as an independent risk predictor for NSCLC prognosis.
• Silencing LINC01214 inhibited NSCLC cell proliferation, migration, and invasion while promoting apoptosis.
• LINC01214 targeted miR-497-3p, which in turn targeted HSP90AB1, forming the LINC01214/miR-497-3p/HSP90AB1 regulatory axis.

Conclusions:

• LINC01214 acts as a potential biomarker contributing to NSCLC progression.
• The LINC01214/miR-497-3p/HSP90AB1 axis promotes NSCLC cell proliferation and motility.
• These findings provide valuable references for NSCLC research and potential therapeutic strategies.